Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Piperacillin and tazobactam for injection is supplied as a powder for
Powder for solution for injection: 2.25, 3.375, 4.5, 40.5 g
STORAGE: Piperacillin and tazobactam vials should be stored at controlled
room temperature, between 20 C to 25 C (68 F to 77 F), before reconstitution.
ADULT DOSING: Piperacillin and tazobactam should be administered by intravenous infusion
(IV) over 30 minutes. The usual daily dose for adults is 3.375 g every six hours (total daily dose
Nosocomial pneumonia: The usual starting dose is 4.5 g intravenously every 6
hours plus an aminoglycoside for 7-14 days.
Community-acquired pneumonia: The usual recommended dose is 3.375 g
intravenously every 6 hours for 7-10 days.
Skin and soft tissue infection: The usual recommended dose is 3.375 mg
intravenously every 6-8 hours for 7-14 days.
Diverticulitis, intra-abdominal abscess, peritonitis: The usual recommended
dose is 3.375 g intravenously every 6 hours for 7-10 days.
Piperacillin and tazobactam requires dose adjustment in patients with reduced
PEDIATRIC DOSING: Manufacturer's recommendation for the treatment of
appendicitis and/or peritonitis includes:
< 2 months: safety and efficacy is not
Infants 2-9 months: 80 mg/kg IV every 8 hours
Infants and children =9 months, weighing =40
kg with normal renal function: 100 mg/kg IV every 8 hours
Pediatric patients > 40 kg with normal renal
function: same as adult dose
Probenecid may inhibit the renal tubular secretion (elimination via the
kidneys) of piperacillin/tazobactam. This may cause higher, prolonged blood
levels of piperacillin/tazobactam. The half-life of piperacillin is prolonged by
21% and the half-life of tazobactam by 71%.
Piperacillin/tazobactam may inhibit platelet aggregation (formation of a
blood clot) which may increase the risk for bleeding. Co-administration with
blood thinning agents such as
warfarin (Coumadin) requires close monitoring for
signs or symptoms of bleeding.
Piperacillin/tazobactam may prolong the neuromuscular blockade of vecuronium
Piperacillin/tazobactam may decrease the renal (kidney) elimination of
methotrexate (Trexall). Patients on concurrent therapy with methotrexate should
be monitored frequently for signs or symptoms of methotrexate toxicity.